Skip to main content
padlock icon - secure page this page is secure

Cost analysis of CHOP (-like) chemotherapy regimens for patients with newly diagnosed aggressive non-Hodgkin's lymphoma

Buy Article:

$59.00 + tax (Refund Policy)

van Agthoven M, Faber LM, Uyl-de Groot CA, Sonneveld P, Verdonck LF, Willemze R, Kluin-Nelemans JC, Löwenberg B, Huijgens PC. Cost analysis of CHOP (-like) chemotherapy regimens for patients with newly diagnosed aggressive non-Hodgkin's lymphoma.

Eur J Haematol 2002: 69: 213–220. © Blackwell Munksgaard 2002. Abstract:

Many cost analyses of stem-cell transplantations are available, which is in sharp contrast to the level of cost analyses on first-line chemotherapy for aggressive non-Hodgkin's lymphoma (NHL). Given the scarcity of cost analyses of first-line chemotherapy for NHL, it is difficult to assess the economic impact of upcoming new treatment modalities. Therefore we performed an analysis on costs of diagnosis and treatment of patients with newly diagnosed NHL who were treated with standard CHOP (-like) chemotherapy. As many NHL patients are treated in trials and the economic effects of the trial participation are unknown, our analysis included both patients treated according to trial protocols and patients treated according to standard local practice (SLP). The cost analysis was based on the total medical consumption of the patients. It was found that costs of the trial and SLP groups are within comparable ranges, although costs of diagnostic tests were somewhat higher within the trials. In elderly patients, SLP chemotherapy was discontinued more frequently in case of leucocytopenia or thrombocytopenia. This analysis provides basic information about the costs of first-line standard chemotherapy for patients with newly diagnosed aggressive NHL and the plausible ranges in which these costs may vary. Given the results, we will initiate larger studies to investigate whether trial treatments (showing more or less similar costs as SLP treatments) are more cost-effective for patients with aggressive NHL.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: chemotherapy; cost analysis; costs; economics; non-Hodgkin lymphoma

Document Type: Research Article

Affiliations: 1: Institute for Medical Technology Assessment, Department of Health Policy and Management, Erasmus Medical Centre, Rotterdam; 2: Department of Haematology, Vrije Universiteit Medical Centre and Boven IJ Hospital, Amsterdam; 3: Department of Haematology, Erasmus Medical Centre, Rotterdam; 4: Department of Haematology, University Medical Centre, Utrecht; 5: Department of Haematology, Leiden University Medical Centre, Leiden; 6: Department of Haematology, University Hospital, Groningen, The Netherlands

Publication date: October 1, 2002

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more